Related Experiment Video

Updated: May 25, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma

Brendan D Looyenga1, Danielle Hutchings, Irene Cherni

  • 1Systems Biology, Van Andel Research Institute, Grand Rapids, Michigan, United States of America. brendan.looyenga@vai.org

Plos One
|February 10, 2012
PubMed

Insights

Constitutive STAT3 activation in non-small cell lung carcinoma (NSCLC) is independent of common driver mutations. Targeting the JAK2/STAT3 pathway inhibits tumor growth, suggesting new therapeutic strategies for NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Constitutive STAT3 activation is prevalent in non-small cell lung carcinoma (NSCLC).
  • STAT3 activation in solid tumors is often linked to growth factor receptors or cytokine signaling, unlike JAK2 mutations in hematologic cancers.
  • The role of STAT3 in NSCLC, particularly its interplay with oncogenic drivers and therapy resistance, remains incompletely understood.

Purpose of the Study:

  • To investigate the mechanisms of STAT3 activation in NSCLC.
  • To determine if STAT3 activation is dependent on known oncogenic driver mutations in NSCLC.
  • To evaluate the therapeutic potential of targeting the JAK2/STAT3 pathway in NSCLC.

Main Methods:

  • Analysis of STAT3 activation in human NSCLC samples and cell lines.
  • Genetic and pharmacologic inhibition of the gp130/JAK2 signaling pathway.
  • Assessment of cell proliferation, viability, soft agar colony formation, and xenograft tumor growth following JAK1/2 inhibition.

Main Results:

  • STAT3 is constitutively activated in NSCLC, independent of KRAS or tyrosine kinase mutations.
  • Inhibition of the gp130/JAK2 pathway effectively disrupts STAT3 activation.
  • The JAK1/2 inhibitor ruxolitinib suppressed NSCLC growth in soft agar and xenograft models, despite no effect on 2D cell cultures.

Conclusions:

  • JAK2/STAT3 signaling is activated independently of common NSCLC driver mutations.
  • Targeting JAK2/STAT3 signaling can inhibit tumor growth in NSCLC models.
  • These findings suggest that JAK2/STAT3 pathway inhibitors may offer therapeutic benefits for NSCLC, potentially overcoming resistance to driver mutation-targeted therapies.

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...